Research Team Creates Human ALS Motor Neurons: First Disease-Specific Stem Cells From Human Skin Cells
Main Category: Stem Cell ResearchAlso Included In: Dermatology; Multiple Sclerosis; Neurology / Neuroscience
Article Date: 03 Aug 2008 - 0:00 PDT
| Patient / Public: | ![]() |
4.33 (9 votes) |
| Healthcare Prof: | ![]() |
5 (1 votes) |
| Article Opinions: | 1 posts |
A team of researchers from the Harvard Stem Cell Institute (HSCI) and Columbia University, in a collaboration catalyzed by the Project A.L.S./Jenifer Estess Laboratory for Stem Cell Research, has demonstrated that pluripotent stem cells generated from a patient with ALS (amyotrophic lateral sclerosis) can be directed to differentiate into motor neurons - the very brain cells destroyed by ALS. The results of the team's study appear in the online issue of Science. This is the first published report to show that disease-specific stem cells may be derived from an individual patient.
In the study, led by Kevin Eggan, of the Harvard Stem Cell Institute, skin cells taken from a patient with a familial form of ALS were induced to become pluripotent stem cells. Scientists then differentiated the pluripotent cells into motor neurons and glia (support cells in the brain) that featured an ALS genotype.
"This is a seminal discovery," said Valerie Estess, director of research for Project A.L.S. "The ability to derive ALS motor neurons through a simple skin biopsy opens the doors to improved drug discovery. For the first time, researchers will be able to look at ALS cells under a microscope and see why they die. If we can figure out how a person's motor neurons die, we will figure out how to save motor neurons."
Starting in 1999, Project A.L.S. recruited leading scientists and clinicians to define the potential role of stem cells in understanding and treating ALS, the fatal neurodegenerative disease, also known as Lou Gehrig's disease. Project A.L.S.-funded scientists began by transplanting stem cells directly into mice with ALS, with limited success. More recent experiments have shown that stem cells may be more valuable as tools to understand the disease process and create mini-representations of disease - or assays - for the purpose of drug screening.
"For the first time, we have the opportunity to examine cellular and molecular defects in motor neurons and glial cells derived from patients with ALS. And we can now begin drug screens on disease-specific classes of human motor neurons," said Thomas Jessell, a Howard Hughes Investigator at Columbia University, and Project A.L.S. advisor. "Through the work of the Jenifer Estess Laboratory for Stem Cell Research we now can glimpse the new age of ALS research, an age of progress and promise."
Co-author on the paper, Christopher Henderson, who is co-director of the Columbia University Center for Motor Neuron Biology and Disease, and senior scientific advisor to the Project A.L.S. Laboratory, said: "It has been a privilege to collaborate with Kevin Eggan and his team and to contribute to this critical step forward. We will continue to work hand-in-hand with Harvard researchers and Project A.L.S. to exploit the potential of these cells for drug screening".
Three years ago, Project A.L.S. asked Dr. Eggan, a stem cell expert, and Chris Henderson, Hynek Wichterle, as authorities on motor neuron biology and drug screening at Columbia University, to work together to understand ALS, one of our most complicated and devastating neurological disorders. This publication marks the first major breakthrough of this collaboration.
###
Project A.L.S. is a non-profit 501©3 whose mission is to understand, treat, and cure ALS, also known as Lou Gehrig's disease. The hallmark of the company's approach is collaboration between researchers and clinicians, many of whom have not focused on ALS specifically, or worked together before. In ten years, Project A.L.S. has raised over $37 million for research worldwide. Located in New York, the Project A.L.S./Jenifer Estess Laboratory for Stem Cell is the world's only privately funded laboratory to focus exclusively on stem cell and ALS. The laboratory was named for Project A.L.S. founder Jenifer Estess, who died from ALS in 2003.
Source: Patricia Harrington
PROJECT A.L.S.
Visit our stem cell research section for the latest news on this subject.
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/116971.php>
APA
http://www.medicalnewstoday.com/releases/116971.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Trials Help
posted by norman pagan on 3 Aug 2008 at 9:37 amI Norman Rene Pagan a 42 year old male living in Puerto Rico am willing to participate in clinical trials concerning stem cell research. I sufered an aneurysm, I'm severely disabled. I have my medical records & a brain scan. I saw you on Yahoo News. I'm not looking to get 100% better but 50 will do fine. Hope you can help me. My disabilities are motor skills - that's why you drew my attention, see this all happend on 9/9/2001 & since then I'm afraid to touch my daughter afraid I might hurt her.
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





